Sign In
Buy RVMD
$155.99
+4.68 (+3.09%)
At Close: Jun 03, 2026
Why Revolution Medicines Stock Is Crashing Today
12:04pm, Monday, 23'rd Oct 2023
Revolution Medicines reported data from a phase 1 study of RMC-6236 in treating lung cancer and pancreatic cancer. High numbers of unconfirmed responses caused investors to be disappointed with the re
Revolution Medicines, Inc. (RVMD) Soars 23.6%: Is Further Upside Left in the Stock?
11:18am, Monday, 16'th Oct 2023
Revolution Medicines, Inc. (RVMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further
Why Shares of Revolution Medicines Were Popping on Friday
02:54pm, Friday, 13'th Oct 2023
Revolution Medicines is a clinical-stage biotech. The company has nearly a million in cash to develop its deep pipeline.
Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
04:05pm, Wednesday, 04'th Oct 2023
Interim Data to be Presented for RMC-6236 (RAS MULTI (ON) Inhibitor) and RMC-6291 (RAS G12C (ON) Inhibitor)
Revolution Medicines: A Big Pipeline In Need Of Big Data
03:24pm, Monday, 25'th Sep 2023
Revolution Medicines, Inc. has a diversified pipeline of drugs but is still searching for its flagship project, making it a high-risk investment. The company is focusing on developing RAS(ON) inhibito
Revolution Medicines, Inc. (RVMD) Q2 2023 Earnings Call Transcript
11:05pm, Tuesday, 08'th Aug 2023
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Erin Graves – Senior Director of Corporate Communications and Investor Relat
Revolution Medicines: Early-Stage Firm Whose High Valuation I Cannot Explain
06:56pm, Tuesday, 11'th Jul 2023
Revolution Medicines, Inc. is undoubtedly doing interesting science. However, I can name 10 companies that are doing equally interesting science but are valued at a fifth of Revolution Medicines stock
Revolution Medicines to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 08'th Jun 2023
REDWOOD CITY, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou
Revolution Medicines, Inc. (RVMD) Q1 2023 Earnings Call Transcript
11:17pm, Monday, 08'th May 2023
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Erin Graves - Senior Director of Corporate Communications and Investor Relations
Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Tops Revenue Estimates
07:02pm, Monday, 08'th May 2023
Revolution Medicines, Inc. (RVMD) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.78 per share a year ago.
Wall Street Analysts Think Revolution Medicines, Inc. (RVMD) Could Surge 27.24%: Read This Before Placing a Bet
11:27am, Wednesday, 03'rd May 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 27.2% in Revolution Medicines, Inc. (RVMD). While the effectiveness of this highly sought-after metric is quest
Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023
04:05pm, Monday, 01'st May 2023
REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
08:07am, Thursday, 20'th Apr 2023
Where is the current bull market? All indications would be that it's in biotech!
Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023
07:00am, Thursday, 06'th Apr 2023
REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today anno
Revolution Medicines, Inc. (RVMD) Q4 2022 Earnings Call Transcript
10:42pm, Monday, 27'th Feb 2023
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Margaret Horn - Chief Operating Officer Mark Goldsmith - Chairman, Presiden
